- Trials with a EudraCT protocol (212)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
212 result(s) found for: Drug Hypersensitivity.
Displaying page 1 of 11.
EudraCT Number: 2009-017828-54 | Sponsor Protocol Number: 1131/09 | Start Date*: 2011-03-28 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Cross-reactivity and tolerability of ertapenem in patients with IgE-mediated allergy to -lactams. | |||||||||||||
Medical condition: allergy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000499-33 | Sponsor Protocol Number: 2006neuro06 | Start Date*: 2007-07-04 | |||||||||||
Sponsor Name:Queen Mary, University of London | |||||||||||||
Full Title: Effects of Pregabalin on acid-induced oesophageal pain hypersensitivity in male and female healthy adult volunteers, as investigated in a single centre, placebo-controlled, double-blind, randomised... | |||||||||||||
Medical condition: This study will test the effects of Pregabalin in a validated model of visceral pain hypersensitivity (VPH) in healthy volunteers. The volunteers must be free of medical conditions. VPH is thought ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003085-12 | Sponsor Protocol Number: ANT-008 | Start Date*: 2022-05-10 |
Sponsor Name:Anthos Therapeutics | ||
Full Title: A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding i... | ||
Medical condition: venous thromboembolism (VTE) in patients with gastrointestinal/genitourinary cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Ongoing) NO (Ongoing) IE (Ongoing) ES (Ongoing) HU (Ongoing) IT (Ongoing) NL (Ongoing) SE (Ongoing) AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003076-14 | Sponsor Protocol Number: ANT-007 | Start Date*: 2022-05-10 |
Sponsor Name:Anthos Therapeutics | ||
Full Title: A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in ... | ||
Medical condition: venous thromboembolism (VTE) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Ongoing) NO (Ongoing) IE (Ongoing) ES (Ongoing) NL (Ongoing) IT (Ongoing) HU (Ongoing) SE (Ongoing) AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004903-20 | Sponsor Protocol Number: ABR-38376 | Start Date*: 2012-05-09 |
Sponsor Name: | ||
Full Title: Hydroxychloroquine as an anti-autophagy and chromatin modulating drug in combination with erlotinib in non-small cell lung cancer (NSCLC) patients: a single-center single arm open-label phase II trial | ||
Medical condition: Patients with histologically confirmed stage IV non-squamous non-small-cell lung cancer (NSCLC) • with an activating EGFR mutation who progressed on erlotinib or gefitinib monotherapy. OR • who... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-004590-30 | Sponsor Protocol Number: R10933-10987-COV-2121 | Start Date*: 2022-09-23 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 2a, Open-Label Study Assessing Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Single-Dose Subcutaneous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab and Imdevim... | |||||||||||||
Medical condition: Coronavirus disease 2019 | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002125-11 | Sponsor Protocol Number: CT-P13-3.5 | Start Date*: 2016-08-23 | |||||||||||
Sponsor Name:Celltrion, Inc | |||||||||||||
Full Title: A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis | |||||||||||||
Medical condition: Active Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) EE (Completed) HU (Completed) CZ (Completed) BG (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001274-17 | Sponsor Protocol Number: CA209-401 | Start Date*: 2016-04-22 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: Clinical Trial of Nivolumab (BMS-936558) Combined with Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects with Histologically Confirmed Stage III (Unresectable) or Stage... | ||||||||||||||||||
Medical condition: Stage III (Unresectable) or Stage IV Melanoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) SE (Completed) IE (Completed) FI (Completed) GB (GB - no longer in EU/EEA) NO (Completed) AT (Completed) BE (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-005180-33 | Sponsor Protocol Number: CNTO328STM2001 | Start Date*: 2009-02-09 | |||||||||||
Sponsor Name:Centocor B.V. | |||||||||||||
Full Title: A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-interleukin 6 (IL-6) Monoclonal Antibody, in Subjects with So... | |||||||||||||
Medical condition: Malignant solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Completed) GB (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023437-30 | Sponsor Protocol Number: A7281006 | Start Date*: 2011-09-29 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-00547659 IN SUBJECTS WITH CROHN’S DISEASE(OPERA) | |||||||||||||
Medical condition: Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) BE (Completed) SE (Completed) AT (Completed) DE (Completed) PT (Prematurely Ended) NO (Completed) NL (Completed) ES (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003810-18 | Sponsor Protocol Number: H9X-MC-GBDE | Start Date*: 2012-07-11 | |||||||||||
Sponsor Name:Eli Lilly & Company | |||||||||||||
Full Title: A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide with Once-Daily Liraglutide in Patients with Type 2 Diabetes (AWARD-6: Assessment of Weekly AdministRati... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) DE (Completed) PL (Completed) ES (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000660-25 | Sponsor Protocol Number: CT-P17_3.2 | Start Date*: 2019-07-09 | |||||||||||
Sponsor Name:CELLTRION, Inc. | |||||||||||||
Full Title: A Phase III, Open-label, Single-arm, Multiple-dose Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients with Moderate to Severe Active Rheumatoid Arthritis | |||||||||||||
Medical condition: Moderate to Severe Active Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001092-49 | Sponsor Protocol Number: VPA-03 | Start Date*: 2015-06-02 | |||||||||||
Sponsor Name:Sahlgrenska Akademien Wallenberglaboratoriet | |||||||||||||
Full Title: Valproic acid regulation of plasma PAI-1 | |||||||||||||
Medical condition: The fibrinolytic system | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005383-42 | Sponsor Protocol Number: BREATH | Start Date*: 2016-05-19 | ||||||||||||||||
Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO | ||||||||||||||||||
Full Title: Use of buspiron in chemioreflex modulation and central apnea treatment in heart failure patients (BREATH: BuspiRon for chEmoreflex modulation and central Apnea treatment in Heart failure patients).... | ||||||||||||||||||
Medical condition: patient with central apneas syndrome and heart failure | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-001745-20 | Sponsor Protocol Number: BP11-301 | Start Date*: 2023-02-02 | |||||||||||
Sponsor Name:CuraTeQ Biologics Private Ltd. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of BP11 Versus EU-Approved Xolair® in Pati... | |||||||||||||
Medical condition: Chronic Spontaneous Urticaria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Ongoing) SK (Ongoing) HU (Ongoing) BG (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004117-24 | Sponsor Protocol Number: GETUG-AFU26 | Start Date*: 2015-12-24 | |||||||||||
Sponsor Name:UNICANCER | |||||||||||||
Full Title: A Phase II Safety Trial of Nivolumab in Patients with Metastatic Renal Cell Carcinoma Who Have Progressed During or After Prior Systemic Anti-Angiogenic Regimen | |||||||||||||
Medical condition: Patients suffering from refractory metastatic Renal Cell Carcinoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003172-43 | Sponsor Protocol Number: TV48125-CNS-30058 | Start Date*: 2017-05-31 |
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | ||
Full Title: A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety of TEV-48125 for the Prevention of Cluster Headache | ||
Medical condition: Cluster headache (CH) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) NL (Completed) PL (Prematurely Ended) FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-004544-32 | Sponsor Protocol Number: CT-P27/2.1 | Start Date*: 2014-02-10 | |||||||||||
Sponsor Name:Celltrion, Inc | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled, single-centre, phase IIa study in healthy volunteers to evaluate the efficacy and safety of CT-P27 in an influenza challenge model | |||||||||||||
Medical condition: Influenza | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004891-36 | Sponsor Protocol Number: NN7415-4307 | Start Date*: 2019-11-20 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B without inhibitors | ||||||||||||||||||
Medical condition: Haemophilia A Haemophilia B | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: DK (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) SK (Prematurely Ended) DE (Trial now transitioned) BG (Temporarily Halted) GB (GB - no longer in EU/EEA) FR (Ongoing) PT (Trial now transitioned) HR (Ongoing) HU (Ongoing) LT (Trial now transitioned) EE (Ongoing) IT (Restarted) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000989-23 | Sponsor Protocol Number: D4881C00024 | Start Date*: 2008-07-01 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A ROLLOVER PROTOCOL FOR PATIENTS WHO RECEIVED TREMELIMUMAB (CP-675,206) IN OTHER PROTOCOLS | |||||||||||||
Medical condition: Patients who have / have had Melanoma and Other Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.